The Atriva Management
Rainer Lichtenberger, Ph.D. MBA
CEO
More than 30 years management in life science Industry, EVP Merckle/ratiopharm group for BD; Since 16 years CEO/COO experience in several SME, raised € 80 Mn venture funds.
Christian Wallasch, Ph.D.
COO
Seasoned executive management member (COO, CEO) in biopharmaceutical SMEs, such as Axxima and U3, as well as public companies like Intercell/Valneva. Expert in kinase inhibitors, vaccines development, project management and execution.
Stephan Stenglein, M.D.
CMO
Physician trained in Clinical and Molecular Virology with 20 years of accomplishments in pharma, medical device and vaccine development. Previous global management positions with Novartis and AstraZeneca.
Prof. Oliver Planz, Ph.D.
CSO
Universität Tübingen (D), Co-inventor of the technology, expert in antiviral research and translational preclinical R&D up to clinical studies. Advises the WHO on antiviral strategies against influenza.
Björn Cochlovius, Ph.D., Assoc. Prof.
VP Business Development
20 years leadership positions in SMEs (Head R&D Affitech, CEO OnTarget) and big pharma (Roche, Otsuka, Abbvie). Working experiences in Europe and Asia. Background in R&D, Business Development, M&A, Financing.
Cees Stouten, M.Sc.
SVP Chemistry Manufacturing Controls,
Site Manager Atriva Therapeutics BV
Accomplished CMC manager with long-standing and deep experience along the entire development, manufacturing and control value chain,
more than 20 years industry experience